[Geneva – 4 January 2019]
Funding supports developing antibiotics for important global health priorities
GARDP is pleased to receive a EUR 1.5 million investment from the German Federal Ministry of Health (MOH). This funding is already contributing to GARDP’s efforts to develop antibiotics for drug-resistant infections including sexually-transmitted infections and newborns with sepsis – both important global health priorities. The investment also supports GARDP’s growth as its incubation period, hosted by DNDi, comes to an end.
[Liverpool, Geneva – 18 December 2018]
The University of Liverpool has signed a collaborative research agreement with GARDP in a bid to develop new treatment options for newborns with sepsis. The research seeks to explore the correct dose and frequency of potential antibiotic combinations that could improve treatment outcomes in this vulnerable population.
Pharmafile [23 July 2018]
“The mission against antimicrobial resistance”
The New Indian Express [12 July 2018]
“‘Antimicrobial drug resistance causing death of newborns’, says new study”
The Hindu [8 July 2018]
“A vigil over neonatal sepsis”
BioSpectrum India [5 July 2018]
“GARDP, WHO, ICMR to collaborate for studying sepsis & AMR”
Mint [5 July 2018]
“Scientists to develop antibiotics for drug-resistant bacterial infections in newborns”
The Hindu Business Line [5 July 2018]
“Drug resistance posing new challenge to child survival”
Millennium Post [5 July 2018]
“Study on new treatments for antimicrobial resistance begins”
Drug Today [4 July 2018]
“Global study to guide new treatment for AMR”
[नयी दिल्ली/ जेनेवा – एम्बार्गो : मंगलवार 3 जुलाई 2018]
अध्ययन का उद्देश्य नये उपचार के विकास के लिए मार्गदर्शन करना व नवजात शिशुओं की मृत्युओं की वैश्विक वृद्धि को उलटना है
ग्यारह देशों के 80 से भी अधिक शोधार्थी नयी दिल्ली में नवजात शिशुओं में सेप्सिस व एंटीबायोटिक निर्देशित करने के मौजूदा तरीकों को समझने के लिए मिल रहे हैं | अवलोकन अध्ययन का नेतृत्व करने के लिए GARDP को बिल एंड मिलिंडा गेट्स फाउंडेशन की ओर से 2 मिलियन अमरीकी डॉलर के ज़रिये बांग्लादेश, भारत, केन्या, दक्षिण अफ्रीका व यूगांडा में अध्ययन के लिए साइट में सहयोग मिल रहा है |
[New Delhi/Geneva – 3 July 2018]
Study aims to guide development of new treatments and reverse global increase in deaths of newborns
Over 80 researchers from 11 countries are meeting in New Delhi today to kick off an observational study to understand sepsis in newborns and current antibiotic prescribing practices. The observational study, led by GARDP, is benefiting from US$2 million funding from Bill & Melinda Gates Foundation.
The Tribune [3 July 2018]
“Scientist to probe causes behind superbug infections in babies”
[26 April 2018]
Funding will support studies on new treatments for neonatal sepsis and drug-resistant STIs in South Africa
GARDP is pleased to announce the strengthening of its collaborative efforts with the SAMRC. This funding will contribute to the global development and delivery of affordable new or improved antibiotic treatments for drug-resistant bacterial infections where there are currently no adequate treatments, beginning with neonatal sepsis and sexually transmitted infections (STIs).
Daily Mail [8 February 2018]
“Drug resistant sepsis is killing newborns”
[Cape Town – 8 November 2017]
Non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) and the Global Antibiotic Research and Development Partnership (GARDP) today opened a new liaison office in Cape Town, South Africa.
by Folgori L, Ellis SJ, Bielicki JA, Heath PT, Sharland M, Balasegaram M.
The Lancet Global Health, November 2017
November 9-11, 2017
Cape Town, South Africa
Manica Balasegaram, Director of GARDP, presented at the event.